‘Velcro protein’ found to play surprising role in cell migration — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/03/140313122538.htm
source : http://www.sciencedaily.com/releases/2014/03/140313122538.htm
source : http://www.sciencedaily.com/releases/2014/03/140311123820.htm
source : http://www.sciencedaily.com/releases/2014/03/140304154523.htm
source : http://www.sciencedaily.com/releases/2014/02/140225122227.htm
source : http://www.sciencedaily.com/releases/2014/02/140214075305.htm
source : http://www.sciencedaily.com/releases/2014/01/140129150730.htm
A report on the discovery, published in the Dec. 5 issue of Science, also suggests that a normal immune system is critical for preventing the development of common types of cancer. According to researchers, patients with scleroderma often make immune proteins or antibodies to another protein, called RPC1. These antibodies are believed to cause the organ damage characteristic of the disease, and the reason behind this antibody production has remained unknown…
A summary of the research, performed on a variety of different animal and human cells, was published online in the Proceedings of the National Academy of Sciences on Nov. 4, and suggests that exemestane’s effectiveness against breast cancer could be due to more than its ability to halt estrogen production, the scientists say. The study’s results further imply that the drug, a so-called aromatase (estrogen synthesis) inhibitor, could potentially be prescribed more widely, including to men, as a way to counteract the wear and tear on cells that often leads to chronic diseases. "Cells already have their own elaborate protective mechanisms, and in many cases they are ‘idling.’ The right drugs and foods can turn them on to full capacity," says Paul Talalay, M.D., the John Jacob Abel Distinguished Service Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine…
"Doctors are looking for new ways to accurately predict prostate cancer patients’ prognoses, because the current methods that use disease stage, Gleason score, and PSA are not perfect," says Alan Meeker, Ph.D., assistant professor of pathology at The Johns Hopkins University School of Medicine and its Kimmel Cancer Center. "Telomere shortening is common in cancer, but the degree of shortening varies from one cancer cell to another within each patient, and this variability may give us a better idea of how prostate cancers behave." In the study, described in the October issue of Cancer Discovery, the scientists studied tissue samples from 596 men surgically treated for prostate cancer thought to be confined to the prostate and who were participants in a long-term follow-up study on men’s health. …
The Food and Drug Administration-approved preservative, an antioxidant called ethoxyquin, was shown in experiments to bind to certain cell proteins in a way that limits their exposure to the damaging effects of Taxol, the researchers say. The hope, they say, is to build on the protective effect of ethoxyquin’s chemistry and develop a drug that could be given to cancer patients before taking Taxol, in much the same way that anti-nausea medication is given to stave off the nausea that commonly accompanies chemotherapy. While half of Taxol users recover from the pain damage, known as peripheral neuropathy, the other half continue to have often debilitating pain, numbness and tingling for the rest of their lives…